Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT)

Pathak, Rima; Pantarotto, Jason; Cook, Graham; Holmes, Oliver; Cross, P.; MacRae, Robert

doi:10.1016/j.ctro.2019.01.003

Cited by 8 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with adenocarcinoma had the lowest prevalence of baseline anemia (29.34%), P<0.001. Our study shows that the proportion of non-smokers is relatively high compared with other study ( 18 ), which may be related to the population of the study. A data from the Asian population published by Zhang shows that the proportion of non-smokers is 42.8% ( 10 ), the proportion of non-smoking patients in our study is similar to Zhang's study.…”

Section: Discussioncontrasting

confidence: 58%

See 1 more Smart Citation

Baseline anemia and anemia grade are independent prognostic factors for stage IV non‑small cell lung cancer

et al. 2021

View full text Add to dashboard Cite

The current study aimed to investigate baseline anemia in patients with stage IV non-small cell lung cancer (NSCLC) and its relationship with clinicopathological features and prognosis. The clinical data of 4,874 patients with stage IV NSCLC were analyzed. The incidence of baseline anemia was observed. The relationship between baseline anemia and clinicopathological features was analyzed. Kaplan-Meier method and multivariate COX regression model were used to analyze the relationship of baseline anemia and prognosis of patients with NSCLC. Anemia classification was based on the criteria established by the National Cancer Institute (NCI). The mean hemoglobin (Hb) was 123.32±20.31 g/l in patients with stage IV NSCLC. The prevalence of baseline anemia was 32.09%, among which 19.08, 10.79, 1.91 and 0.31% had mild, moderate, severe, and life-threatening anemia, respectively. The prevalence of baseline anemia was higher in patients who were >60 years old, male, had smoking history, exhibited squamous cell carcinoma and bone metastasis, and the difference was statistically significant. Univariate analysis indicated that patients without anemia had longer overall survival (OS) compared with patients with baseline anemia (median OS: 28.0 months vs. 17.4 months, P<0.001). As the grade of anemia rises, it was indicated that OS became shorter. Patients with anemia grade 0 had the longest OS (median OS: 28.0 months), followed by patients with anemia grades 1 and 2 (median OS: 17.5 months). The patients with anemia grades 3 and 4 had the shortest OS (median OS: 8.6 months; P<0.001). Multivariate analysis demonstrated that baseline anemia and anemia grade were independent prognostic factors in patients with stage IV NSCLC. In conclusion, baseline anemia and anemia grade are independent prognostic factors in patients with stage IV NSCLC.

show abstract

Section: Discussioncontrasting

confidence: 58%

“…According to previous studies on anemia and lung cancer prognosis, radiotherapy and chemotherapy are the main methods used to treat lung cancer ( 10 , 12 , 13 , 18 , 19 ). In the past decade, targeted therapy and immunotherapy have changed the treatment mode of advanced lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Baseline anemia and anemia grade are independent prognostic factors for stage IV non‑small cell lung cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Pathak et al . evaluated 487 patients with stage I NSCLC treated with stereotactic body radiation therapy (SBRT) and reported that patients with anemia before treatment had increased local recurrence and distant metastasis rates; additionally, the OS rate of these patients was significantly lower …”

Section: Discussionmentioning

confidence: 99%

“…33 Pathak et al evaluated 487 patients with stage I NSCLC treated with stereotactic body radiation therapy (SBRT) and reported that patients with anemia before treatment had increased local recurrence and distant metastasis rates; additionally, the OS rate of these patients was significantly lower. 34 The potential diagnostic or prognostic significance of RDW in malignant tumors has also attracted increasing attention in recent years. Koma et al 35 retrospectively analyzed the data of 332 patients with lung cancer, including 109 women and 223 men who were divided into groups according to RDW values of ≥15% and <15%; the findings of their study confirmed that high levels of RDW are associated with advanced stage disease and indicate poor prognosis in the patients.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of baseline hemoglobin‐to‐red blood cell distribution width ratio in small cell lung cancer: A retrospective analysis

Yang

Tang

et al. 2020

Thoracic Cancer

View full text Add to dashboard Cite

Background This study aimed to investigate the prognostic value of baseline hemoglobin‐to‐red blood cell distribution width ratio (HRR) in patients with small cell lung cancer (SCLC). Methods We retrospectively analyzed the medical records of patients with newly diagnosed SCLC who had received first‐line chemotherapy at the Department of Pulmonary Oncology of the PLA 307 Hospital between January 2008 and October 2018. The optimal cutoff value of the continuous variables was determined using the X‐tile software. Univariate and multivariate analyses were conducted using Cox proportional hazard models. The Kaplan‐Meier method was used for survival analysis, with differences tested using the log‐rank test. Results A total of 146 patients were included. The cutoff value for HRR was determined as 0.985. Statistically significant differences were observed in sex, smoking history, stage, radiotherapy combination, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio, hemoglobin, and red blood cell distribution width between the high and low HRR groups. The median overall survival (OS) was nine and 17.5 months in the low and high HRR groups, respectively (P < 0.001). The median progression‐free survival (PFS) was five and 8.5 months, respectively (P < 0.001). Univariate and multivariate analyses showed low HRR to be an independent predictor of a poor prognosis for OS (hazard ratio = 3.782; 95% confidence interval, 2.151–6.652; P < 0.001) and PFS (hazard ratio = 2.112; 95% confidence interval, 1.195–3.733; P = 0.01) in SCLC. Conclusion Low HRR was associated with poorer OS and PFS in patients with SCLC and can be a potentially valuable prognostic factor for these patients. Key points The prognostic value of the baseline hemoglobin‐to‐red blood cell distribution width ratio was evaluated in patients with small cell lung cancer. In this population, this ratio was an independent predictor of overall survival and progression‐free survival. This ratio, an inexpensive and routine parameter, can be used as a prognostic factor in small cell lung cancer.

show abstract

“…However, there is limited literature available on the prognostic significance of anemia in patients with NSCLC undergoing SBRT. 18 , 19 The purpose of this study was to evaluate the association between pre-treatment anemia and prognosis in patients with NSCLC treated with SBRT.…”

Section: Introductionmentioning

confidence: 99%

Anemia is a Prognostic Factor for Overall Survival Rate in Patients with Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy

Tanaka

Ono

Manabe

et al. 2021

CMAR

View full text Add to dashboard Cite

Purpose Anemia has been associated with poor prognosis in patients with cancer across several cancer types. It has been identified as a prognostic factor in patients with non-small cell lung cancer (NSCLC) who have undergone surgery or chemoradiotherapy. However, there are only a few reports that have evaluated the prognostic significance of anemia in patients with NSCLC undergoing stereotactic body radiation therapy (SBRT). Patients and Methods A total of 77 patients were enrolled in this study. The pretreatment hemoglobin (Hb) levels, within 2 weeks before SBRT, were available for all patients. The median age of the participants (56 men, 21 women) was 80 (range, 50–90) years. The median Hb level was 12.8 (range, 7.8–18.3) g/dL. The median follow-up period was 24 (range, 1–87) months. Results Local recurrence was observed in 8 (10.4%) cases during the follow-up period. The 1- and 2-year local control (LC) rates were 94.8% and 86.4%, respectively. Seventeen (22.1%) patients died during the follow-up period. The 1- and 2-year overall survival (OS) rates were 93.1% and 85.2%, respectively. Univariate analysis identified anemia and body mass index as significant prognostic factors for predicting OS. On multivariate analysis, anemia was confirmed to be the only significant factor (p = 0.02469). Conclusion Our data suggest that anemia is a prognostic factor for predicting the OS rate in patients with early-stage NSCLC treated with SBRT.

show abstract

Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT)

Cited by 8 publications

References 39 publications

Baseline anemia and anemia grade are independent prognostic factors for stage IV non‑small cell lung cancer

Baseline anemia and anemia grade are independent prognostic factors for stage IV non‑small cell lung cancer

Prognostic value of baseline hemoglobin‐to‐red blood cell distribution width ratio in small cell lung cancer: A retrospective analysis

Anemia is a Prognostic Factor for Overall Survival Rate in Patients with Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy

Contact Info

Product

Resources

About